Successful allogeneic SCT in infant with FHL, dilemmas in using „unaffected“ sibling P.Sedláček, R. Špíšek, et al 2nd Medical School, Charles University,

Slides:

Advertisements

Similar presentations

Cord Blood Transplantation: Umbilical Blood As Hematopoietic Stem Cell Source Analysis of theoretical/clinical advantages/disadvantages Comparison with.

Advertisements

Minimal Residual Disease in Hematologic Neoplasms Lloyd M. Stoolman, M.D. Professor of Pathology and Director, Clinical and Research Flow Cytometry Laboratories.

Case no. 7. Eva Honsova Institute for Clinical and Experimental Medicine Pathology Department Prague, Czech Republic

Primary deficiencies of the complement system Radana Zachová Institute of Immunology Faculty hospital Prague, Motol.

Hemolytic Disease of the Newborn Case #3

Dao-Pei Lu May 2010, Shanghai Hematopoietic Stem Cell Transplantation (HSCT) in China (2010)

Transplantation of hematopoietic stem cells in pediatric oncology Vladivostok State Medical University Foreign languages department Vladivostok 2012 Scientific.

Severe combined immune deficiency in Nablus Omar Abuzaitoun, MD.

University of Wisconsin Newborn Screening for SCID Experience: Spanning the Spectrum Christine Seroogy MD Associate Professor Pediatric Allergy, Immunology.

Allogeneic Stem Cell Transplantation: The Journey

Hematopoietic Stem Cell Transplant

SUDHA KOLLA. HISTORY “Bubbly boy disease” “Bubbly boy disease” Known and discovered in 1970’s and 80’s Known and discovered in 1970’s and 80’s David Vetter.

In Vitro Fertilization and Preimplantation Genetic Diagnosis

Diagnosis of Primary Immunodeficiency

History 2: 70 year old female

Tolerance Induction after Kidney Transplantation Stephan Busque MD M Sc FRCSC Director, Adult Kidney and Pancreas Transplantation Program Stanford University.

Graft vs Host Disease Remains the major cause of treatment related morbidity and mortality in allogeneic HCT. Caused by donor derived alloreactive T cells.

What about stem cell transplantation? Dr Catherine Flynn Consultant Haematologist St James’s Hospital 17/06/2011.

Blood Component Therapy

Therapeutic management in a boy with XL-CGD complicated by invasive aspergillosis. Department of Immunology Children’s Memorial Health Institute Warsaw.

A Retrospective Study of Outcomes in Pediatric Hematology/Oncology Patients Receiving Continuous Venovenous Hemodialysis Y Avent 1, N Henderson 1, T Collie.

LIBYAN EXPERIENCE IN PEDIATRIC ACUTE MYELOID LEUKEMIA Fathia El Riani, Rasem Al Ajnef, Elham Sbita, Salem Zarroug Departement of pediatric hematology-oncology.

HSCT in a patient with hyper IgM syndrome - our recent experience -

P-CID patient discussion form. Patient summary y/o boy/girl with: – Infection – Immune dysregulation – T cell deficiency Consanguinity: Family history:

Burst test using FagoFlow in patients with CGD and hematopeotic stem cell transplantation Andrea Poloučková, M.D. Department of Immunology, Charles University,

BENIN BLOOD & MARROW TRANSPLANT SOCIETY OF NIGERIA JULY STEM CELL TRANSPLANT CENTRE, BENIN Graft versus Host Disease in HSCT Anthony Oyekunle.

Impact of a PRUDENT © Red Blood Cell Transfusion Strategy in Pediatric HSCT and Oncology Patients Results from the CHB Experience © 2009 All rights.

Bone marrow Transplant in Paediatric Haematology

Suspected hemophagocytosis in EBV infection P. Rozsíval, E. Pařízková, P. Dědek, T. Chyba Department of Pediatrics University Hospital Hradec Králové Charles.

Adenosine-Deaminase (ADA) Deficiency ADA is responsible gene in ~20% SCID. Often fatal, if untreated, due to infections. It was the first form of SCID.

Transplantation of Tissues and Organs

Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation, Year New transplant patients Deaths

Follow-up of a patient with CERNUNNOS deficiency Edyta Heropolitańska-Pliszka Immunology Department Children’s Memorial Health Institute Warsaw, Poland.

Hepatitis B Fahad Alanazi.

1 CASE REPORT hematology Monika Csóka MD, PhD year old boy no abnormalities in previous anamnesis 2 weeks before viral infection (fever, coughing)

PID patients in Motol Radana Zachová Institute of Immunology University hospital Prague Motol, Czech Republic ESID Prague Spring meeting 2005.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Natural Killer Cells:

Donor lymphocyte infusion as a treatment of a complete DiGeorge syndrome K.Zdráhalová 2, E.Mejstříková 1,2,T.Kalina 1,2,P.Sedláček 2, A. Janda 1, H.Žižková.

Dr. Kasi Viswanathan, Head Dept. Of Haematology & Bone marrow transplantation Dept. Of Pediatric Oncology, Meenakshi Mission Hospital & Research Centre,

Blood Transfusion Reaction in neonates & management

Abo incompatible stem cell transplant: laboratory side

Treatment of Aplastic Anemia

Time to neutrophil engraftment Time to platelet engraftment

Leishmaniasis Thomas Fourie MD M. Taher Shabani-Rad MD CLS, Division of Hematopathology.

Haematopoietic stem cell transplantation alongside enzyme replacement therapy in infantile onset lysosomal acid lipase deficiency Ghosh A1, Lum SH2, Jones.

Case Western Reserve University and University Hospitals of Cleveland

Indication of Blood Transfusion in Newborns Dr Bijan Keikhaei Full Professor of Pediatric Hematology and Oncology Research Center for Thalassemia and.

CASE PRESENTATION DR SANJAY MAITRA, DR DENISH SAVALIA,

Supplementary Figure S1

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular.

Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors Mitchell S. Cairo,

A novel immunoregulatory role for NK-cell cytotoxicity in protection from HLH-like immunopathology in mice by Fernando E. Sepulveda, Sophia Maschalidi,

Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.

Interesting Case Conference

Letermovir(Prevymis™) Guidelines for Inpatient Use

Qualitative and quantitative PCR monitoring of minimal residual disease (MRD) in relapsed poor-risk chronic lymphocytic leukemia (CLL): early assessment.

BMT AND THALASSAEMIA DR. MD. SALAHUDDIN SHAH

بسم الله الرحمن الرحیم.

Blood Groups/Types.

Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients.

Beta thalasemia.

Normal Immunologic Response to a Neoantigen, Bacteriophage ΦX-174, in Baboons With Long-Term Lymphohematopoietic Reconstitution From Highly Purified CD34+

Is KIR- typing relevant to HCT donor selection?

by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A

NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation by Louise E. Hogan,

Bridge to transplant following Bv+Bs regimen.

Frédéric Baron, Rainer Storb

Dr Ghssemi Ali Associate Professor of Pediatric Hematologist & Oncologist & stem cell transplantation.

How I treat acquired aplastic anemia

Presentation transcript:

Successful allogeneic SCT in infant with FHL, dilemmas in using „unaffected“ sibling P.Sedláček, R. Špíšek, et al 2nd Medical School, Charles University, Prague, CZ ESID – May

Past Medical History (family) mother HBsAg +, no transf.history father – OK 1st girl – died 32nd gest.week (umb. cord problems) 2nd boy (IVF) – Jakub – alive/well 3rd girl (IVF) - Jana * July 8 th 2003

History of Present Illness I – early postnatal pancytopenia (WBC : 4,8, RBC: 3,1, ret.: 0,1%, ANC: <100, Plt 11) allo HLA Ab in mother exchange transfusion (D+9), PRBC, Plt, Fbg HSmegaly, hepatopathy, hypertriglycemia, hyperbilirubinemia hyperferritinemia ( >18 000) DIC, infections, fever and elev. CRP, HBsAg and HBeAg negative (Engerix, Hepatect) Admission to our department at the age of 28 days (Aug.2003)

History of Present Illness II Day of admission Aug. 5th 2003 –liver +4cm, spleen +3-4cm bcm, pancytopenia Therapy according to HLH 94 –(VP16, Dexa, CsA) –discontinued for acute sepsis Transfusion history pre SCT –PRBC 13 x (or more) –Plt more than 13

Pre-transplant condition HSmegaly, ferritin 3153 antiHBc and antiHBe pos., HBsAg neg. Failure to thrive (bw 3,45 kg; 2,8 kg at birth) normal LFT; Plt 100, WBC and RBC normal brother fully HLA matched, 19kg bw, 3yo ABO incompat. : A+ vs. B- (low titers)

Diagnostics-1 FACS analysis of perforin expression in NK cells Exclusion of FHL type 2- perforin deficiency Patient´s NK cells Control 87% of NK cells are perforin + Brother´s NK cells Control

Diagnostics-2 Cytotoxic activity of T-lymphoblasts generated from T-cells Target cells: L1210 cells deficient in FAS expression % cytotoxicity patient brother control defective cytotoxic activity of patient´s lymphoblasts normal findings in her brotherdonor of SC X

Transplantation (* ) Bu(19mgkg) + Cy(200) + rATG(25mg/kg) CsA + MP (MTX not used due to early and severe VOD) BM : NC : 8,9x 10 8 /kg; CD34: 22x10 6 /kg VOD : D+1 (D-3 through D+15 defibrotide) –Bilirubinemia, thrombocytopenia, ascites, ARDS Engraftment :ANC (500) D+19; Plt (20/50) D+22/+26 Chimer. : stable, 95% donor Discharched to outpatient clinic D+34 no aGVHD, no cGVHD so far (~D+240) –continues on CsA, steroids D/C ~D+50 –growth catch-up

Acknowledgement Department of Pediatric Hematology and Oncology –HSCT unit; Division of Hematology Institute of Immunology –diagnostics of primary HLH Institute of Hematology and Blood Transfusion –HLA typing